Physician profile
John Patrick Rice
NPI 1538546874
$6,408.42
in general payments reported to CMS, 2019-2025
31 companies · $982 in 2025
The $982 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,779 · 2022: $1,968 · 2023: $1,317 · 2024: $363 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.86 |
| Education | $118.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,754.84 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $663.62 | 2021-2025 | Otezla, Repatha, Enbrel |
| Abbvie INC. | $634.89 | 2021-2025 | |
| Lilly USA, LLC | $477.53 | 2021-2025 | Mounjaro, Trulicity, Taltz |
| Astrazeneca Pharmaceuticals LP | $459.37 | 2021-2024 | Farxiga, Breztri, Saphnelo |
| Bayer Healthcare Pharmaceuticals INC. | $292.27 | 2021-2023 | |
| Amarin Pharma, INC. | $260.21 | 2021-2023 | |
| Abbott Laboratories | $234.85 | 2022-2023 | Freestyle Libre 3 |
| Ucb, INC. | $191.21 | 2024-2025 | Bimzelx, Cimzia |
| Janssen Pharmaceuticals, INC | $164.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.62 | 2021-2024 | Ofev |
| Teva Pharmaceuticals USA, INC. | $143.20 | 2025 | Austedo Xr |
| Glaxosmithkline, LLC. | $134.14 | 2022 | |
| Organon LLC | $106.89 | 2024-2025 | Renflexis, Hadlima |
| Pfizer INC. | $100.28 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $96.19 | 2022-2023 | |
| Genentech USA, INC. | $82.49 | 2024-2025 | Actemra |
| Novartis Pharmaceuticals Corporation | $72.01 | 2025 | |
| Xeris Pharmaceuticals, INC. | $60.59 | 2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $51.22 | 2022 | |
| Sk Life Science, INC. | $41.51 | 2025 | |
| Nestle Healthcare Nutrition INC. | $38.28 | 2021 | |
| Sanofi Pasteur INC. | $32.89 | 2025 | |
| Neurocrine Biosciences, INC. | $32.27 | 2025 | |
| Astellas Pharma US INC | $23.60 | 2023 | Veozah |
| Lundbeck LLC | $21.98 | 2025 | Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.73 | 2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $19.62 | 2024 | |
| Fresenius Kabi USA, LLC | $19.45 | 2024 | Idacio |
| Argenx US, INC. | $17.26 | 2025 | Vyvgart Hytrulo |
| Eisai INC. | $14.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.